Concepedia

Massimo Guidoboni

MG

Statistics

Publications

61

Citations

15.1K

H-Index

33

Active since

1990

Affiliations

Istituti di Ricovero e Cura a Carattere Scientifico(Current)

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Centro di Riferimento Oncologico

European Institute of Oncology

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Massimo Guidoboni is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in oncology, melanoma immunotherapy, and cancer immunotherapy.

ORCID

Publications per year

1990–2024

61

Publications

61

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text

, , +17

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2019 · 3.7K citations · Full text

, , +14

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · Zurich Open Repository and Archive (University of Zurich) · 2022 · 557 citations

, , +17

Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas

Andrés J.M. Ferreri, Massimo Guidoboni, Maurilio Ponzoni et al. · JNCI Journal of the National Cancer Institute · 2004 · 556 citations · Full text

, , +10

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion‐Sileni, Piotr Rutkowski et al. · New England Journal of Medicine · 2024 · 480 citations · Full text

, , +14

1–5 of 61